Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20(+) Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study

PURPOSE: Obinutuzumab (GA101), a novel glycoengineered type II anti-CD20 monoclonal antibody, demonstrated responses in single-arm studies of patients with relapsed/refractory non-Hodgkin lymphoma. This is the first prospective, randomized study comparing safety and efficacy of obinutuzumab with rit...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Sehn, Laurie H., Goy, Andre, Offner, Fritz C., Martinelli, Giovanni, Caballero, M. Dolores, Gadeberg, Ole, Baetz, Tara, Zelenetz, Andrew D., Gaidano, Gianluca, Fayad, Luis E., Buckstein, Rena, Friedberg, Jonathan W., Crump, Michael, Jaksic, Branimir, Zinzani, Pier Luigi, Padmanabhan Iyer, Swaminathan, Sahin, Deniz, Chai, Akiko, Fingerle-Rowson, Günter, Press, Oliver W.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2015
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5087315/
https://ncbi.nlm.nih.gov/pubmed/26282650
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.59.2139
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki